21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
20:21 , Mar 30, 2018 |  BioCentury  |  Product Development

Perception into pain

Against the backdrop of the snowballing opioid crisis, drugmakers are aiming to get new therapies to patients faster by making pain trials more efficient and lower risk. New patient stratification methods are contributing to the...
01:03 , Jan 6, 2018 |  BC Extra  |  Company News

Pfizer ending discovery, early neuroscience program

Pfizer Inc. (NYSE:PFE) said Friday it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the...
00:07 , Dec 22, 2017 |  BC Innovations  |  Strategy

Ovid spreads its wings

With its first two candidates for rare neurological disorders heading towards clinical proof of concept, Ovid Therapeutics Inc. is looking to capitalize on the experience it has gained to find compounds with differentiated pharmacology that...
00:32 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

FDA approves Pfizer's Lyrica CR for DPN, PHN pain

FDA approved Lyrica CR from Pfizer Inc. (NYSE:PFE) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN), but did not approve the drug for the management of fibromyalgia....
21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round...
00:04 , Sep 28, 2017 |  BC Extra  |  Financial News

Venture roundup: Engage, Integra

On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million in a series A round led...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
02:15 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Lyrica regulatory update

Pfizer and Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said Japan approved Lyrica pregabalin oral disintegrating (OD) tablets to treat neuropathic pain and pain associated with fibromyalgia. The GABA receptor agonist is already available as capsules....
17:57 , Jan 19, 2017 |  BC Innovations  |  Translation in Brief

Pockets against pain

Amgen Inc. (NASDAQ:AMGN) is aiming to tackle neuropathic pain by boosting glycine receptor α 3 ( GLRA3 ) activity in the CNS. In a December study, the company presented preclinical data and crystal structures for...